Nicholas Saccomano Insider Profile
11 Followers
Nicholas Saccomano, President & CEO, Director at OnKure Therapeutics, holds 11.25K shares in OnKure Therapeutics (Ticker: OKUR), holds 0.00 shares in Array Biopharma (Ticker: ~ARRY), holds 150.19K shares in Array Technologies (Ticker: ARRY).
Nicholas Saccomano has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Nicholas Saccomano holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Nicholas Saccomano
Nicholas Saccomano's Trading History
OnKure Therapeutics
Jun 24, 2026
President & CEO, Director
Uninformative Sell
377.54
$32.39K
Array Biopharma
Jul 30, 2019
―
Uninformative Sell
7.21M
$0.00
Array Technologies
Apr 03, 2019
CSO
Uninformative Buy
189.47K
$630.80K
List of latest transactions for each holding click on a transaction to see Nicholas Saccomano's performance on stock
You May Also Like
Nicholas Saccomano insider profile FAQ
What is the percentage of profitable transactions made by Nicholas Saccomano?
The percentage of profitable transactions made by Nicholas Saccomano is ―.
What is the average return per transaction made by Nicholas Saccomano?
The average return per transaction made by Nicholas Saccomano is ―.
What stocks does Nicholas Saccomano hold?
Nicholas Saccomano holds: OKUR, ~ARRY, ARRY stocks.
What was Nicholas Saccomano’s latest transaction?
Nicholas Saccomano latest transaction was an Uninformative Sell of $377.54.
What was Nicholas Saccomano's most profitable transaction?
Nicholas Saccomano’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Nicholas Saccomano's role in OnKure Therapeutics?
Nicholas Saccomano's role in OnKure Therapeutics is President & CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.